Pancreas

Hyperacute-Pancreatic cancer vaccine

Description:

This Phase III study is for patients with pancreatic cancer who have had surgical resection. Patients will be randomized to receive adjuvant therapy, Gemcitabine or 5-FU chemoradiation with or without immunotherapy with HyperAcute Pancreatic Cancer Vaccine.


Type(s) of Cancer: Pancreas
Study Phase(s): Phase III
Contact: Epp Goodwin at (210) 450-5798

M402

Description:

M402 is a heparin sulfate mimetic designed to have antitumor effect without the anticoagulant activity. In this Phase I/II study M402 is administered as daily subcutaneous injection with Gemcitabine in patients with metastatic pancreatic cancer who have not received prior chemotherapy.


Type(s) of Cancer: Pancreas
Study Phase(s): Phase I
Phase II
Contact: Epp Goodwin at (210) 450-5798